


## Reserpine

Cat. No.:	HY-N0480
CAS No.:	50-55-5
Molecular Formula:	C <sub>33</sub> H <sub>40</sub> N <sub>2</sub> O <sub>9</sub>
Molecular Weight:	608.68
Target:	Monoamine Transporter; Autophagy
Pathway:	Membrane Transporter/Ion Channel; Autophagy
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (41.07 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	1.6429 mL	8.2145 mL	16.4290 mL
				5 mM	0.3286 mL	1.6429 mL	3.2858 mL
				10 mM	0.1643 mL	0.8214 mL	1.6429 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.11 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.11 mM); Clear solution						

### BIOLOGICAL ACTIVITY

Description	Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
IC <sub>50</sub> & Target	VMAT2 <sup>[1]</sup>
In Vitro	Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2). Reserpine displays a significant effect on the density of dopamine D1 receptors (F <sub>2,12</sub> =8.81, p<0.01) in the rat striatum. The affinity (Kd) for the dopamine D1 and D2 receptors during withdrawal from acute and chronic administration of reserpine is not change <sup>[1]</sup> . IC <sub>50</sub> values of 43.9 and 54.9 μM are obtained after 1 day of treatment with Reserpine in JB6 P+ and HepG2-C8 cells, respectively. Reserpine induces luciferase activity in a dose-dependent manner at concentrations ranging from 5 to 50 μM, and no significant induction is observed at concentrations lower than 5 μM. Results demonstrate that Reserpine (2.5 to 10 μM) also increases the protein expression of Nrf2, HO-1, and NQO1. Reserpine at concentrations of 2.5 to 10 μM decreases the mRNA expression of DNMT1,

DNMT3a, and DNMT3b in a concentration-dependent manner in JB6 P+ cells after 7 days of treatment. Reserpine at 10  $\mu$ M generates a significant difference for DNMT3a expression ( $p < 0.05$ )<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Reserpine can be used in animal modeling to construct gastrointestinal ulcer models.

Withdrawal (48 h) from chronic (14-day) but not acute Reserpine administration in a dose of 0.2 mg/kg i.p. produces a significant reduction of the immobility time ( $F_{2,18}=3.68$ ,  $p < 0.05$ ), but increases the climbing time ( $F_{2,18}=4.48$ ,  $p < 0.02$ ), and does not change the swimming time ( $F_{2,18}=1.78$ ; NS) in the forced swim test (FST) in rats<sup>[1]</sup>. Reserpine at a dose of 5 mg/kg body weight produces significant increase in the urinary excretion profile of vanillylmandelic acid (VMA) compare to control animals. The amount of 5-hydroxyindoleacetic acid (5-HIAA) excreted in animals treated with Reserpine is found to be more than in the control. Dose dependent hypotension is observed with Reserpine. Reserpine at doses of 0.5, 1, 5, 10 and 15  $\mu$ g/kg produce significant ( $p < 0.01$ ) reduction in blood pressure compare to control<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Kinase Assay <sup>[2]</sup>

After incubation for 24 h, JB6 P+ cells ( $1 \times 10^5$  cells/10-cm dish) are treated with various concentrations of Reserpine. Whole cell lysates are prepared from the treated cells using radioimmunoprecipitation assay buffer supplemented with a protease inhibitor cocktail, and a BCA kit is used to determine protein concentrations<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Assay <sup>[2]</sup>

JB6 P+ cells are seeded in 96-well plates containing Minimum essential media (MEM) at a density of  $1 \times 10^4$  cells/mL (100  $\mu$ L/well) for 1, 3, and 5 days, and HepG2-C8 cells are seeded in plates containing DMEM. After incubation for 24 h, the cells are treated with either DMSO or various concentrations of Reserpine. For JB6 P+ cells, the medium is changed every 2 days for the 3-day and 5-day treatments. Cell viability is assessed using a MTS assay kit according to the manufacturer's instructions. The absorbance of the formazan product is read at 490 nm, and the cell viability is calculated and compared with the DMSO control group<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration <sup>[3]</sup>

Albino rats of either sex weighing between 100 to 150 g are used in the study. They are acclimatized to the laboratory conditions for at least 10 days prior to the experiment and provided with standard diet and water ad libitum with 12 h light and dark cycle. Animals are divided into different groups of six each and are housed individually in metabolic cages. Group 1: Control animals treated with DMSO intraperitoneally at a dose of 0.1 mL/100 g body weight. Group 2: Animals administered intraperitoneally with Reserpine at a dose of 5 mg/kg body weight. The 24 h urine samples from the point of drug administration are collected for each animal<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Crit Rev Anal Chem. 2021 Mar 10;1-15.
- Nigerian Journal of Scientific Research. 18 (3): 2019.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Pfeiffer CJ, et al. Reserpine-induced gastric ulcers: protection by lysosomal stabilization due to zinc. Eur J Pharmacol. 1980 Feb;61(4):347-53.

- 
- [2]. Li GJ, et al. Preventive Effect of Polysaccharide of *Larimichthys crocea* Swim Bladder on Reserpine Induced Gastric Ulcer in ICR Mice. *Korean J Physiol Pharmacol*. 2014 Apr;18(2):183-90.
- [3]. Gupta MB, et al. Mechanism of ulcerogenic activity of reserpine in albino rats. *Eur J Pharmacol*. 1974 Jul;27(2):269-71.
- [4]. Park BK, et al. Antidepressant-Like Effects of Gyejibokryeong-hwan in a Mouse Model of Reserpine-Induced Depression. *Biomed Res Int*. 2018 Jun 26;2018:5845491.
- [5]. El-Marasy SA, et al. Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence. *Chem Biol Interact*. 2021 Jan 25;334:109329.
- [6]. Antkiewicz-Michaluk L, et al. Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: a behavioral and neurochemical ex vivo and in vivo studies in the rat. *Prog Neuropsychopharmacol Biol Psychiatry*. 2015 Mar 3;57:146-54.
- [7]. Hong B, et al. Reserpine Inhibit the JB6 P+ Cell Transformation Through Epigenetic Reactivation of Nrf2-Mediated Anti-oxidative Stress Pathway. *AAPS J*. 2016 May;18(3):659-69.
- [8]. Sreemantula S, et al. Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats. *BMC Pharmacol*. 2004 Nov 16;4:30.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA